The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?


  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Allergan
  • Biocon
  • Celltrion
  • Dr. Reddy's
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Viatris (Mylan)
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Shanghai Henlius Biotech

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Enbrel
  • Erbitux
  • Eylea
  • Forteo
  • Herceptin
  • Humira
  • Lantus
  • Lucentis
  • Neulasta
  • Neupogen
  • Prolia / Xgeva
  • Remicade
  • Rituxan / MabThera
  • Xolair

Table of contents

  • Biosimilars - Emerging Biosimilars - Emerging Biosimilars Landscape
    • Emerging Biosimilars Landscape
      • Biosimilars Pipeline Analysis
        • Biosimilars Development Pipeline by Phase of Development
        • Biosimilars Development Pipeline by Class
        • Biosimilars Development Projects by Reference Molecule
        • Top 10 Biosimilars Development Projects by Reference Molecule
        • Leading Biosimilars Developers
        • Top Biosimilars Developers by Number of Clinical-Stage Biosimilars in the Major Markets
        • Top Biosimilars Developers by Number of Clinical-Stage Biosimilars, Excluding the Major Markets
        • Timeline of Expected Biosimilar Launch Dates in the United States
        • Timeline of Expected Biosimilar Launch Dates in the EU
        • Timeline of Expected Biosimilar Launch Dates in Japan
      • Appendix
        • Methodology
        • Terminology in Biosimilar Pipeline

Author(s): Yashu Malhotra; Hamzah Aideed, M.Sc.

Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.

Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.